Nammi Therapeutics Granted FDA Orphan Drug Designation for QXL138AM for the Treatment of MM

Nammi Therapeutics
Jun 13, 2022
1 min read

FDA has granted orphan drug designation (OOD) to Nammi Therapeutic's lead program, QXL138AM, for the treatment of multiple myeloma. QXL 138AM is a Masked Immunocytokine targeting a masked interferon alpha to the CD138 receptor on the surface of tumor cells.

Recent Posts

See All

Nammi Therapeutics, Inc. Announces First Patient Dosed with QXL138AM in a Phase 1 Study Evaluating Advanced Solid Tumors and Multiple Myeloma

Nammi Therapeutics, Inc., a clinical stage immuno-oncology company with a diverse pipeline created with the Masked-Immunocytokine (MIC)...

Nammi Therapeutics Completes Series B Round with Investment from MMRF's Myeloma Investment Fund

Nammi Therapeutics announces a $1M investment commitment by the Myeloma Investment Fund in a $30M Series B financing round prior to the...

Nammi Therapeutics Featured in Los Angeles Business Journal

Nammi Therapeutics was featured in the Los Angeles Business Journal. The article featured an interview with David Stover, President and...

Commentaires